Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab After Immunotherapy in Head and Neck Squamous Cell Carcinoma
NCT04375384Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Wake Forest University Health Sciences. Started Jul 2020; status: recruiting.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04375384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375384.